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Abstract
Benefit-risk assessment is a crucial step in the medical decision process.
In many biomedical studies, both longitudinal marker measurements and time
to a terminal event serve as important endpoints for benefit-risk assessment.
The e↵ect of an intervention or a treatment on the longitudinal marker process,
however, can be in conflict with its e↵ect on the time to the terminal event. Thus
questions arise on how to evaluate treatment e↵ects based on the two endpoints,
for the purpose of deciding on which treatment is most likely to benefit the
patients. In this dissertation, we present a unified framework for benefit-risk
assessment using the observed longitudinal markers and time to event data. We
propose a cumulative weighted marker process to synthesize information from
the two endpoints, and use its mean function at a pre-specified time point as
a benefit-risk summary measure. We consider nonparametric estimation of the
summary measure under two scenarios: (i) the longitudinal marker is measured
intermittently during the study period, and (ii) the value of the longitudinal
marker is observed throughout the entire follow-up period. The large-sample
properties of the estimators are derived and compared. Simulation studies and
the application to an AIDS clinical trial exhibit that the proposed methods are
easy to implement and reliable for practical use.
In many follow-up or surveillance studies, marker data are collected con-
ditioning on the occurrence of recurrent events. In contrast with the above
situation that the marker measurements exists at any time before the termi-
nal event, sometimes marker measurements are triggered by the occurrence of
ii
recurrent events. Examples include the medical cost for inpatient or outpa-
tient cares, length-of-stay for hospitalizations, and prognostic or quality-of-life
measurement repeatedly measured at multiple infections related to a certain
disease. A recurrent marker process, defined between a pre-specified time origin
and a terminal event, is composed of recurrent events and repeatedly measured
marker measurements. We consider nonparametric estimation of the mean re-
current marker process in the situation when the occurrence of terminal event is
subject to competing risks. Statistical methods and inference are developed to
address a variety of questions and applications, for the purposes of estimating
and comparing the integrated risk in relation to recurrent events, marker mea-
surements and time to the terminal event for di↵erent competing risk groups. A
SEER-Medicare linked database is used to illustrate the proposed approaches.
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and Yan Li, and my fiancé, Yiyang Pan. Their unconditional love are the




Table of Contents vi
List of Tables x
List of Figures xii
1 Introduction 1
1.1 Overview of Statistical Problems . . . . . . . . . . . . . . . . . 1
1.1.1 Benefit-risk assessment using marker process and time-to-
event data . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.2 Recurrent marker process in the presence of competing
terminal events . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Motivating Examples . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2.1 CPCRA ddI/ddC data . . . . . . . . . . . . . . . . . . . 3
1.2.2 SEER-Medicare linked database for breast cancer . . . . 4
1.3 Organization . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2 Literature Review 7
2.1 Statistical Methods for Longitudinal marker and Time-to-Event
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
vi
2.2 Statistical Methods for Cost/Utility Data . . . . . . . . . . . . . 9
3 Benefit-risk Assessment Using Marker Process in the Presence
of a Terminal Event 10
3.1 Cumulative Weighted Marker Process and Benefit-Risk Assessment 10
3.2 Nonparametric Estimation of µ(t) When Marker is Intermittently
Observed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.2.1 A kernel smoothing approach . . . . . . . . . . . . . . . 14
3.2.2 A computationally more e cient approach . . . . . . . . 17
3.3 Nonparametric Estimation of µ(t) When Marker is Continuously
Observed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
3.4 Two-Sample Test . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.5 Simulation Studies . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.5.1 Simulation when Y (·) is intermittently observed . . . . . 23
3.5.2 Simulation when Y (·) is continuously observed . . . . . . 27
3.6 Proofs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.6.1 Proof of Theorem 3.2.1 and 3.2.2 . . . . . . . . . . . . . 29
3.6.2 Proof of Theorem 3.3.1 and comparison of asymptotic
variance of µ̂A(t) and µ̃(t) . . . . . . . . . . . . . . . . . 33
3.6.3 Proof of Lemma 3.6.1 . . . . . . . . . . . . . . . . . . . . 35
3.6.4 Proof of Lemma 3.6.2 . . . . . . . . . . . . . . . . . . . . 36
4 Recurrent Marker Process in the Presence of Competing Ter-
minal Events 41
4.1 Recurrent Marker Processes . . . . . . . . . . . . . . . . . . . . 41
4.2 Nonparametric Estimation in Non-Competing Risks Model . . . 44
vii
4.3 Nonparametric Estimation in Competing Risks Model . . . . . 46
4.4 Improved Estimation in Competing Risks Model . . . . . . . . . 49
4.5 Simulation Studies . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.6 Proofs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.6.1 Proof of Theorem 4.2.1 . . . . . . . . . . . . . . . . . . . 55
4.6.2 Proof of Theorem 4.3.1 . . . . . . . . . . . . . . . . . . . 57
4.6.3 Proof of Theorem 4.4.1 . . . . . . . . . . . . . . . . . . . 59
4.6.4 Proof of Corollary 4.4.2 . . . . . . . . . . . . . . . . . . 60
5 Analysis of Quality-of-life outcomes and Medical Costs Data:
Application to AIDS and Cancer Studies 62
5.1 Analysis of Quality of life and Survival: CPCRA ddI/ddC Trial 62
5.2 Analysis of Censored Medical Cost Data: SEER-Medicare Linked




3.1 Simulation summary statistics for µ̂A(t) and µ̂B(t) . . . . . . . . 26
3.2 Empirical power of two-sample test when Y (·) is intermittently
observed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.3 Empirical power of two-sample test where Y (·) is a function of
recurrent event process . . . . . . . . . . . . . . . . . . . . . . . 29
4.1 Simulation summary statistics for  ̂impj ,  ̂j and  ̃j . . . . . . . . 54
5.1 Analysis of ddI/ddC trial of CPCRA . . . . . . . . . . . . . . . 65
5.2 Analysis of SEER-Medicare Data . . . . . . . . . . . . . . . . . 68
ix
List of Figures
3.1 M(t) (area of shaded region) when terminal event occurs before
t (left panel) and terminal event occurs after t (right panel), in
the special case where w(·) = 1. . . . . . . . . . . . . . . . . . . 11
5.1 Estimated cumulative mean functions µ(t) using Karnofsky score
and time to death (left), survival functions (middle) and mean
Karnofsky score of survivors E{Y (t) | D   t} (right) for ddI
(solid line) and ddC (dashed line) treatment groups. . . . . . . . 64
5.2 Estimated total mean cost over time since first diagnosis of breast
cancer and point-wise 95% confidence intervals . . . . . . . . . . 68
5.3 Cost analysis for breast cancer mortality and cardiovascular dis-
ease mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69




1.1 Overview of Statistical Problems
1.1.1 Benefit-risk assessment using marker process and
time-to-event data
Assessing benefits and risks is a crucial step in the medical decision making pro-
cess. The purpose of benefit-risk assessment is to determine whether the benefits
of an intervention or treatment outweigh its risks based on a given measure. In
many clinical trials or biomedical studies, a conventional way of risk assessment
is to analyze the time to an event of interest. Statistical methods such as the
log-rank test and Cox’s proportional hazards model are widely used for risk as-
sessment based on the event time. On the other hand, longitudinally measured
patient-centered outcomes or biomarkers are also frequently collected, because
they characterize patients’ health status and quality of life over time. For exam-
ple, in the Didanosine/Zalcitabine trial conducted by Terry Beirn Community
Programs for Clinical Research on AIDS (CPCRA) (Abrams et al., 1994), time
to AIDS progression or death is the primary endpoint; moreover, the Karnof-
sky score, which quantifies patients’ general well-being and physical quality of
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life, is assigned by study investigators at each follow-up visit. The longitudinal
marker measurements, such as quality of life score, o↵er insights into patients’
experience and perceptions and serve as important endpoints in evaluating a
treatment. Thus question arises on how to assess benefits and risks based on
both time to event and longitudinal marker, for the purpose of deciding on
which treatment is most likely to benefit the patients.
1.1.2 Recurrent marker process in the presence of com-
peting terminal events
In biomedical or prospective follow-up studies, longitudinal data are typically
collected or observed with pre-specified or random sampling times where sam-
pling times do not have specific biological or medical implications. In contrast,
recurrent marker data are a type of repeated measurements, where the sam-
pling times are recurrent event times, and a marker measurement is collected
or observed conditioning on the occurrence of a recurrent event. In many situ-
ations, marker measurement does not even exist unless a recurrent event takes
place. Examples include multiple medical cost for inpatient or outpatient cares,
prognostic or quality-of-life measurement repeatedly measured at incidences of
infections, and length-of-stay measurement for recurrent hospitalizations. In
reality, the recurrent marker process could be terminated by a failure event
such as death, and competing risks arise when subjects are exposed to several
causes of terminal event (Kalbfleisch and Prentice, 2002). Besides analyzing
recurrent marker data over time without discriminating the types of terminal
event, investigators are also interested in the performance of recurrent marker
process for subjects with a specific type of terminal event. This article presents
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a framework for nonparametric estimation of recurrent marker process in the
presence of competing terminal events.
1.2 Motivating Examples
1.2.1 CPCRA ddI/ddC data
The Community Programs for the Clinical Research on AIDS (CPCRA) was
established to study the e↵ectiveness of various treatments for HIV. Comprised
of 17 research units that represent a significant diversity of ethnicity, geography
and risk group, the CPCRA provides opportunity of clinical research on patients
underrepresented in traditional, university-based HIV studies. The CPCRA
ddI/ddC study was designed to address the important clinical question of which
one of the currently available nucleoside analogues should be given to a patient
who can no longer tolerate or has failed ZDV therapy.
The CPCRA ddI/ddC study opened in December 1990 and enrolled 467
patients by September 20, 1991. Among the 467 subjects, 230 were randomized
to receive ddI and 237 to receive ddC. All patients were followed for at least one
year after the last patient was enrolled. As mentioned above, Karnofsky score is
measured at each follow-up visit. Moreover, occurrence of all the opportunistic
infections, which indicates deterioration in patients’ health, is also recorded. At
the end of study, 88 patients from the ddC group and 100 patients from the ddl
group died; and the death terminates the existence of Karnofsky score as well
as the occurrence of opportunistic infections. In this study, prolonged survival
time is desired, but is not the only goal of the treatments. In chapter 3, we
develop statistical methods for deciding which treatment is better based on (i)
3
Karnofsky score and time to death, (ii) Opportunistic infections and time to
death.
1.2.2 SEER-Medicare linked database for breast cancer
The linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data
are a large population-based source of information for cancer-related health
services research in the United States. The SEER-Medicare data for breast
cancer patients provide detailed information about Medicare beneficiaries with
breast cancer, including clinical, demographic, cause-of-death information and
the Medicare claims for covered health care services from the time of a person’s
Medicare eligibility until death. Specifically, each Medicare claim includes the
date of service, diagnostic codes and amounts for charges. The medical cost
accumulation process is an example for recurrent marker process, since charges
was recorded when each recurrent health service occurred.
There are di↵erent possible types of death for a breast cancer patient, in-
cluding death from a toxic reaction to the therapy, an isolated local recurrence,
development of a second type of cancer and so on. Thus, in addition to study
the total medical cost, information on medical costs attributed to di↵erent types
of failure may also be useful. Our work is the first attempt to develop statisti-
cal methods to study medical cost accumulation process when competing risk
is present.
1.3 Organization
In this dissertation, we consider two types of marker process with terminal
events, and develop statistical methods and inference to address a variety of
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questions and applications related with the two types of data.
For the first type of data, marker exist at any time before the terminal
event, for example, the marker can be quality of life or biomarkers. In the
context of synthesizing information from both the terminal event process and
the longitudinal marker process, we develop a unified framework for benefit-risk
assessment to to facilitate decision-making. A summary measure integrating
the two outcomes is proposed, including the expected quality-adjusted survival
time as a special case. We consider di↵erent nonparametric approaches for the
summary measure under two scenarios: (i) the longitudinal marker is measured
intermittently until terminal event or loss to follow-up, and (ii) the value of the
longitudinal marker is observed throughout the entire follow-up period. The
contents of this topic are organized as follows: In Chapter 3.1, we define cu-
mulative weighted marker process and use its mean function at a pre-specified
time point as a summary measure for benefit-risk assessment. In Chapter 3.2,
we consider nonparametric estimation of the mean function of the cumulative
weighted marker process when the longitudinal marker is intermittently ob-
served. In Chapter 3.3, a nonparametric estimator of the mean function is
proposed when the longitudinal marker is continuously observed. In Chapter
3.4, two-sample tests based on the proposed summary measure is developed. In
Chapter 3.6, we report the results of some simulation studies.
For the second type of data, the marker measurement exists conditioning
on the occurrence of a recurrent event, for example, the marker can be medical
cost or length of stay associated with each hospitalization. In Chapter 4.1, a
point process for recurrent events is generalized to a recurrent marker process by
accounting for additional information from markers as well as risk types. A mean
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function is defined with or without competing risks specification. In Chapter 4.2,
we consider nonparametric estimation for the mean function without competing
risks specification. In Chapter 4.3, a di↵erent approach is proposed for the
mean function with competing risks specification. In Chapter 4.4, an improved
estimator of the mean function under competing risks model is proposed for an
e ciency gain. In Chapter 4.5, simulation studies are presented.
In Chapter 5, we present the statistical analysis of two sets of data. First,
the CPCRA ddI/ddC data serve as an example of how to conduct benefit-
risk assessment based on quality of life and survival time. Second, analysis of
the SEER-Medicare breast cancer data is presented to illustrate the proposed
methodology on recurrent marker process, with a special focus on competing
risks model. The medical costs for sujbects with di↵erent causes of death are
carefully studied to understand the cost accumulation patterns.





2.1 Statistical Methods for Longitudinal marker
and Time-to-Event Data
Because the longitudinal measurements and time to the event are often corre-
lated in nature, the occurrence of the terminal event can induce informative
drop-out to the collection of longitudinal markers. Thus a conventional longitu-
dinal data analysis which fails to account for the correlated terminal event can
result in biased estimation. In the literature, many authors have proposed to
employ a joint model of the longitudinal marker process and the terminal event
time process to make valid inference. For example, Wu and Carroll (1988),
Tsiatis et al. (1995) and Hogan and Laird (1997) linked the two outcome pro-
cesses via subject-specific random e↵ects, while Henderson et al. (2000), Wang
and Taylor (2001) and Xu and Zeger (2001) considered using a time-varying
latent process to link the two processes. Although the joint modeling approach
is appropriate for describing treatment e↵ects on the longitudinal marker and
the time to the terminal event separately, it may be inadequate for decision-
making. If a treatment has favorable e↵ects on both endpoints, the decision is
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straightforward; however, if one treatment shows an advantage on survivorship
but a disadvantage on longitudinal marker, then the decision is more di cult
to make. In the latter scenario, a summary measure that integrates information
from event time and longitudinal marker is desired, and decision can be made
by comparing the summary measure across di↵erent treatments.
Quality-adjusted survival analysis (Gelber et al., 1989; Glasziou et al., 1990)
is a useful tool that incorporates survival time and quality of life into a summary
measure. By weighting the durations of di↵erent health states by their respec-
tive utility values, a single endpoint is constructed to summarize the duration
of survival and the quality of life. Nonparametric estimation of the expected
quality-adjusted survival time has been studied by many authors, including
Huang and Louis (1999), Shen et al. (1999), Zhao and Tsiatis (1999) and Mur-
ray and Cole (2000). When the transitions between health states are unclear or
if they do not adequately reflect variations in quality of life, Hwang et al. (1996)
and Glasziou et al. (1998) considered using quality of life measures over time as
the utility weight, instead of assigning a fixed weight to a specific health state.
In Hwang et al. (1996), in addition to a cohort study from which the survival
function of the time to the terminal event is readily estimable, another cross-
sectional survey needs to be conducted in order to estimate the quality-of-life
weight. The validity of the estimator then relies on the assumption that the
subjects in the cross-sectional survey must be a random sample from the origi-
nal cohort study population. To ensure an accurate decision-making process, it
is desirable to develop standardized and validated methodologies for studying
quality-adjusted survival.
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2.2 Statistical Methods for Cost/Utility Data
In the absence of competing risks, numerous nonparametric methods have been
developed for estimating the total utility or cost at a pre-specifed time hori-
zon. Huang and Louis (1998) studied nonparametric estimation of the joint
distribution of a survival time and a mark variable or vector, where an impor-
tant example of mark variable is the lifetime utility or cost. Lin et al. (1997),
Bang and Tsiatis (2000), Strawderman (2000), Zhao and Tian (2001) proposed
nonparametric estimators of the mean of the mark variable. Moreover, Huang
(2002) and Sun et al. (2009) developed semiparametric models for inference on
mark variable and survival outcome. In the literature, estimation of recurrent
marker processes under competing risks models has never been considered. In
the presence of competing risks, because the failure type is typically unknown
for censored subjects, existing methods in the aforementioned papers are not
directly extendable to estimate the mean utility or cost attributed to a specific
failure type. In this dissertation, we analyze the recurrent marker data over
time, with a special focus on competing risks model. The proposed methods
are also relevant to the quality-of-life research. Specifically, when the marker
is a quality-of-life measurement, the methodology can be extended to quality-





Marker Process in the Presence
of a Terminal Event
3.1 Cumulative Weighted Marker Process and
Benefit-Risk Assessment
Let {Y (t), t   0} be a longitudinal marker process, where Y (t) is a nonnegative
marker measurement at time t. Denote the time to the terminal event of interest
byD, whereD is possibly correlated with marker process Y (·). Here we consider
benefit-risk assessment based on the time to the terminal event and the longi-
tudinal marker process before the terminal event, that is, {Y (t), D; 0  t  D},
as the value of Y (·) after D is either not defined or not of interest. For ease
of discussion, we assume that a larger marker value indicates a more favorable




w(u)Y (u)I(D   u)du,
where w(u) is a pre-specified weight function and Y (u)I(D > u) is a marker
process that takes the value 0 after the terminal event. In the special case
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where w(·) = 1, M(t) is the area under the marker trajectory before the time
point t or the terminal event, whichever occurs first, as shown in Figure 3.1.
Note that M(t) can be viewed as an endpoint that integrates information from
both the longitudinal marker process and the survival time. An ideal treatment
or intervention should prolong survival while maintaining higher marker values

















Figure 3.1: M(t) (area of shaded region) when terminal event occurs before t
(left panel) and terminal event occurs after t (right panel), in the special case
where w(·) = 1.
Taking expectation of M(t), we define the cumulative mean function
µ(t) = E{M(t)} =
Z t
0
w(u)E{Y (u)I(D   u)}du.
This gives the area under curve for the weighted mean function w(u)E{Y (u)
I(D   u)}. In the special case where w(·) = 1 and Y (·) = 1, µ(t) reduces to the
restricted mean survival time up to t (Irwin, 1949); moreover, in the absence of
the terminal event, µ(t) =
R t
0 E{Y (u)}du is the area under the expected marker
trajectory up to t (Sun and Wu, 2003). The weight function w(·) can be set to
reflect the clinical importance of a marker at di↵erent time points. For example,
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if achieving a high marker value at earlier time points is more important than
that at later time points, then w(·) can be set as a nonincreasing function of
time. We propose to use µ(⌧), the cumulative mean function at a pre-specified
time point ⌧ , as a benefit-risk summary measure, where a treatment with higher
value of µ(⌧) is preferred. In what follows, we consider two scenarios to illustrate
the use of the proposed summary measure.
Example 3.1.1 (Quality of life and survival). With advances in treatment and
supportive care, treatment decision-making for patients with advanced cancer
are increasingly complex. Because cure is elusive for thse patients, it has been
recognized that prolonging survival is not the only goal of treatment and that
maintaining quality of life is also an important outcome, as patients may be
unwilling to accept worse quality of life to achieve longer survival. To integrate
quality of life and survival into clinical decision analysis, we let D be the time
to death and Y (t) be the quality of life measurement at t. In the special case
where w(·) = 1, µ(⌧) is the mean quality-adjusted survival time restricted to
time ⌧ . Comparison based on µ(⌧) can assist investigators to evaluate trade-o↵s
between survival and quality of life.
Example 3.1.2 (Multiple events and survival). In many longitudinal studies,
the occurrence of multiple events are commonly encountered and serve as im-
portant endpoints. For the Beta-Blocker Evaluation of Survival Trial (The Beta
Blocker Evaluation of Survival Trial Investigators, 2001), an advanced chronic
heart failure clinical trial, in addition to overall survival, which is the primary
endpoint of the study, clinical outcomes such as hospitalization, myocardial in-
farction, and heart transplantation are also of interest. We denote by T1, T2
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and T3, the time of the three secondary endpoints, and by D the time to death.
To incorporate information from the multiple event process, one can define
Y (t) =
P3
i=1 I(Ti   t) + 1. Then the stochastic process Y (·), which decreases
by 1 when any one of the three non-fatal events occurs, can be viewed as a score
that reflects patients’ disease burden and health condition over time. By setting
w(·) = 1, the summary measure µ(⌧) = E{
P3
i=1 min(Ti, D, ⌧) + min(D, ⌧)} is
the expected sum of four types of event-free survival times up to ⌧ (Claggett et
al., 2014 - manuscript in preparation).
Note that in the first scenario the longitudinal maker process Y (·) is usually
measured at intermittent time points, while in the second scenario Y (·) is com-
pletely observed throughout the follow-up period. We then develop di↵erent
estimating procedures corresponding to the two types of observed data.
3.2 Nonparametric Estimation of µ(t)WhenMarker
is Intermittently Observed
In this section, we consider nonparametric estimation of the cumulative mean
function µ(t) (0  t  ⌧) in the case where the longitudinal marker process Y (·)
is measured intermittently. In practice, the survival time D is subject to right
censoring due to study end or premature dropout. We denote the censoring time
by C and assume that C is independent with {Y (·), D}. Define X = min(D,C)
and   = I(D  C). Let N⇤(·) be the counting process for the potential
data collecting times of the marker Y (·), where the rate function of N⇤(·) is
 ⇤(t), that is, E{dN⇤(t)} =  ⇤(t)dt, t   0. Then the counting process N(t) =
I(X   t)N⇤(t) gives the number of observations of the marker before time t,
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that is, Y (·) is observed only at the time points where N(·) jumps. We further
assume that N⇤(·) is independent with {D,C, Y (·)}, then the rate function of
the observation time process N(t) is  (t) = SX(t) ⇤(t) with SX(t) = Pr(X   t).
In other words,  (t) gives the instantaneous “risk” of the marker being measured
at time t. The observations {Xi, i, Yi(t)dNi(t), 0  t  ⌧, i = 1, . . . , n} are
assumed to be independent replicates of {X, , Y (t)dN(t), 0  t  ⌧}.
Two major challenges lie in the estimation of µ(t) = E{M(t)}. First, be-
cause Y (·) is observed at discrete time points during the course of follow-up,
the cumulative weighted marker process M(t) is not evaluable. Second, even in
the ideal case that Y (·) is completely observed up to X, the induced informa-
tive censoring hampers the development of statistical methods. Although it is
usually reasonable to assume that the terminal event time D and the censoring
time C are independent, M(D) and M(C) are usually positive correlated. For
example, a healthier subject may maintain a higher marker value over time,
hence having larger M(C) as well as M(D). The naive method of treating
{Mi(Xi), i : i = 1, . . . , n} as right censored data and estimating the distribu-
tion of M(D) using the Kaplan-Meier estimator can result in substantial bias.
In what follows, we propose two consistent estimators for µ(t) and study their
large-sample properties.
3.2.1 A kernel smoothing approach
To construct a nonparametric estimator for µ(t) =
R t
0 w(u)E{Y (u)I(D   u)}du,




w(u)SD(u)E{Y (u) | D   u}du, (3.2.1)
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where SD(u) = Pr(D   u) is the survival function of D and r(u) = E{Y (u) |
D   u} is the expected marker value of survivors at time u. Under independent
censoring, subjects in the risk set at time u are a representative sample of event-
free individuals at time u in the target population. As a result, it can be shown











0 Kh(u  s)I(Xi   s)dN
⇤
i (s)
, u 2 [h, ⌧   h], (3.2.2)
where Kh(x) = h 1K(x/h) is a kernel function with bandwidth h, and K(·)
satisfies
R 1
 1 K(x)dx = 1 and
R 1
 1 xK(x)dx = 0. It is easy to see that r̂h is
a locally weighted average of nearby marker values and is a natural extension
of the Nadaraya-Watson estimator. If the uniform kernel is employed, that
is, K(x) = I(|x| < 1)/2, the denominator of r̂h(u) is the total number of
observations in the time interval [u  h, u+ h], while the numerator is the sum
of all the observed marker value in [u  h, u+ h]. To avoid biased estimates in
the boundary region [0, h) and (⌧   h, ⌧ ], we set r̂h(u) = r̂h(h) for u 2 [0, h),
and r̂h(u) = r̂h(⌧   h) for u 2 (⌧   h, ⌧ ]. It is shown in Appendix 3.6.3 that
r̂h(·) is uniformly consistent on [0, ⌧ ].
Replacing E{Y (u) | D   u} with r̂h(u) and SD(u) with the Kaplan-Meier





Theorem 3.2.1 summarizes the large-sample properties of µ̂A(t). DefineMDi (t) =
NDi (t) 
R t
0 I(Xi   u)d⇤
D(u), where ⇤D(t) is the cumulative hazard function of
D and NDi (t) = I(Di  t, i = 1).
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Theorem 3.2.1. Under Assumptions (A1)-(A5) in Appendix 3.6.1, the stochas-
tic process n1/2{µ̂A(t)  µ(t)} (0  t  ⌧) has an asymptotically i.i.d. represen-
tation n1/2{µ̂A(t)  µ(t)} = n 1/2
Pn



















w(u)SD(u)E{Y (u)I(X   u)}I(Xi   u)dN⇤i (u)
 (u)SX(u)
.
Moreover, as n ! 1,
p
n{µ̂A(t)  µ(t)} (0  t  ⌧) converges weakly to a zero
mean Gaussian process with the variance-covariance function E{ 1(s) 1(t)}.
It is worthwhile to point out that the main technical challenge in proving
p
n-
consistency of µ̂A(t) is that the Kaplan-Meier estimator ŜD(·) is
p
n-consistent
while the kernel-type estimator r̂h(·) is
p
nh-consistent, thus commonly used
techniques such as functional delta method can not be directly applied. It
is shown in Appendix 3.6.1 that, by under smoothing r(u) using bandwidth
h = O(n ⌫) (1/4 < ⌫ < 1/2), µ̂A(t) can achieve
p
n-consistency.
Remark 3.2.1. Although, as a common practice, marker values of survivors
are summarized and analyzed for treatment comparison, caution should be paid
when interpreting the function r(u) = E{Y (u) | D   u}, because the survivor
population changes over time and may not be representative of the originally
randomized population defined at time zero. To see this, suppose D and Y (·)
are correlated through a frailty Z, where a larger value of Z inflates the risk of
the terminal event and decreases the value of marker process simultaneously. If
a treatment decreases the risk of the terminal event but does not a↵ect Y (·), it
can be shown that E(Z | D   u) of the treatment group is larger than or equal
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to that of the control group at any time u. As a result, the survivors, based
on which inference for r(u) are drawn, are not comparable between treatment
and controls as the terminal event occur along the time. In this case, r(u) of
treatment group may be lower than or equal to that of the control group. Hence
comparisons based on r(u) may yield incorrect conclusion about the treatment
e↵ects on the longitudinal marker process.
3.2.2 A computationally more e cient approach
In practice, numerical integration is employed to approximate the integral in
(4.2.2). Thus the estimated curve r̂h(u) needs to be evaluated at a large number
of grid points. To reduce the computational burden, we consider an alternative
estimator that does not require numerical integration in evaluating the estima-
tor. Specifically, the second estimator is motivated by the equality
E{Y (u)I(X   t)dN⇤(u)} = E{Y (u) | D   u} (u)du,
which holds under the assumption that N⇤(·) is independent of {Y (·), D, C}





 1E{Y (u)I(X   u)dN⇤(u)}.
Note that Y (u)I(X   u)dN⇤(u) is a stochastic process that takes nonzero values
only at the time when dN⇤(u) > 0, so the stochastic process is completely
observed and its mean function E{Y (u)I(X   u)dN⇤(u)} can be consistently
estimated by its empirical average n 1
Pn
i=1 Yi(u)I(Xi   t)dN⇤i (u). Then a









w(u)ŜD(u)Yi(u)I(Xi   u)dN⇤i (u)
 ̂h(u)
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0 Kh(u  s)dNi(s) is a nonparametric smoothed esti-
mator estimator for the rate function  (u). Note that  ̂h(·) can be viewed as
an extension of kernel density estimator proposed by Wang and Chiang (2002).
As before, we set  ̂h(u) =  ̂h(h) for u 2 (0, h] and  ̂h(u) =  ̂h(⌧   h) for
u 2 [⌧   h, ⌧ ] to avoid boundary e↵ect of the kernel estimator. Theorem 3.2.2
summarizes the large sample properties of µ̂B(t), with proofs given in Appendix
3.6.1.
Theorem 3.2.2. Under the assumptions in Theorem 3.2.1, the stochastic pro-
cess n1/2{µ̂B(t)   µ(t)} (0  t  ⌧) has an asymptotically i.i.d. representa-
tion n1/2{µ̂B(t)   µ(t)} = n 1/2
Pn
i=1 i(t) + op(1). Moreover, as n ! 1,
p
n{µ̂B(t)   µ(t)} (0  t  ⌧) converges weakly to a zero mean Gaussian pro-
cess with the variance-covariance function E{ 1(s) 1(t)}.
Interestingly, the two nonparametric estimators µ̂A(t) and µ̂B(t) are asymp-
totically equivalent. Note that the latter evaluates the smoothed function  ̂h(·)
only at the time when marker values are observed, while the former evaluates
the smoothed function r̂h(·) on a much finer grid for numerical integration.
Hence µ̂B(t) is computationally more convenient than µ̂A(t). The simulation
study in Section 5 shows that the two estimators have similar performance with
finite sample size, we then recommend the use of µ̂B(t) to estimate µ(t). For
the standard error estimation, the variance-covariance function E{ 1(s) 1(t)}
can be consistently estimated by n 1
Pn
i=1





















w(u)ŜD(u)r̂h(u)I(Xi   u)dN⇤i (u)
 ̂h(u)
,





 1dNDi (u) is the Nelson-Aalen estimator of




0 I(Xi   u)d⇤̂D(u).
3.3 Nonparametric Estimation of µ(t)WhenMarker
is Continuously Observed
In this section, we consider estimation of µ(t) when the longitudinal marker
process Y (·) is completely observed before the terminal event or censoring. The
observed data {Xi, i, I(Xi   t)Yi(t) : 0  t  ⌧, i = 1, . . . , n} are assumed to
independent replicates of {X, , I(X   t)Y (t) : 0  t  ⌧}. As in Section 3,
the key step is to estimate the function r(u) = E{Y (u) | D   u}. Under the
independent censoring assumption, for u 2 [0, ⌧ ], we propose to estimate r(u)
by the moment type estimator
r̃(u) =
Pn
i=1 Yi(u)I(Xi   u)
Pn
i=1 I(Xi   u)
.





Note that the moment-type estimator r̃(u) is a
p
n-consistent estimator for
r(u), while the kernel-type estimator r̂h(u) in (3.2.2) has a
p
nh convergence
rate. Interestingly, µ̃(t) can be shown to be more e cient than µ̂A(t) and µ̂B(t).
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Theorem 3.3.1 states the asymptotic properties of µ̃(t), with proof given in
Appendix 3.6.2.
Theorem 3.3.1. Under Assumptions (A1) and (A2) in Appendix 3.6.1, the
stochastic process n1/2{µ̃(t)   µ(t)} (0  t  ⌧) has an asymptotically i.i.d.
representation n1/2{µ̃(t)  µ(t)} = n 1/2
Pn



















w(u)SD(u)E{Y (u)I(X   u)}I(Xi   u)
SX(u)2
du.
Moreover, as n ! 1,
p
n{µ̃(t)   µ(t)} (0  t  ⌧) converges weakly to a zero
mean Gaussian process with the variance-covariance function E{U1(s)U1(t)}.
Moreover, E{U1(t)}2  E{ 1(t)}2 for all t 2 [0, ⌧ ].
An important application of the proposed methods is benefit-risk assessment
that combines information from a multiple event process and a terminal event
(see Example 3.1.2 in Section 3.1). Let O(·) denote the multiple event counting
process that increase by one when a non-terminal event occurs. For ease of
discussion, assume that a smaller value of O(·) at any time point is preferred.
To perform benefit-risk assessment based on {X, ,I(X   t)O(t) : 0  t  ⌧},
we set Y (t) to be a function of O(t), say, Y (t) = f{O(t)}, where f is a pre-
specified non-increasing function with f(·)   0. In this case, Y (t) can be viewed
as a score that characterizes patient’s disease burden and health condition, and
a larger value of Y (t) is desired. Without loss of generality, we set w(·) = 1
since the weight function can be absorbed into f .
In practice, the function f can be determined by the investigators. We
consider two choices of f for illustration. As suggested by Claggett et al.
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(manuscript in preparation), a simple approach is to define a truncated reverse
counting process with f(x) = (K   x)I(K   x) + 1, where K is a pre-specified
integer. In this way, only the firstK non-terminal events are of interest and Y (·)
stays 1 after the Kth event until the terminal event occurs. Another approach
is to define f(x) = ax, where 0 < a < 1. Then each subject starts with a score
of 1, and the occurrence of a non-terminal event at time t discounts a patient’s
score Y (t) by a factor of a. In contrast with the truncated reverse counting
process approach, all the non-terminal events are of interest. We recommend
the use of second approach when the number of event of interest that can be
potentiallly observed is not fixed.
3.4 Two-Sample Test
In this section, we consider nonparametric tests for comparing the benefit-risk
summary measure µ(⌧). Suppose there are two groups, say, group 1 and group
2. The notation used in this section is defined in a way similar to that in
Section 3.2, with subscript j indicating the jth group. Assume that both
groups can be potentially observed up to time ⌧ . Let µj(⌧) be the mean func-
tion of the cumulative weighted marker process at time ⌧ for group j, that is,
µj(⌧) =
R ⌧
0 w(u)E{Yj1(u)I(Dj1   u)}du, j = 1, 2. Consider the null hypothe-
sis H0 : µ1(⌧) = µ2(⌧) for two-sample comparison. Let nj be the number of
subjects in the jth group, n = n1 + n2, and let ⇡j = limn!1 nj/n, j = 1, 2.
In this section, w(·) is either known for can be consistently estimated from
data by ŵ(t). A possible choice of ŵ(t) is the Gehan-type weight function
ŵ(t) = {nŜX1(t)ŜX2(t)}/{n1ŜX1(t) + n2ŜX2(t)}, where ŜXj(t) is the empirical
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survival function of Xj1, j = 1, 2.
We consider testing H0 in two scenarios: (i) When the marker process Y (·)
is intermittently observed, corresponding to the two estimators in Section 3.2,
two simple test statistics can be constructed as
WA = µ̂A1(⌧)  µ̂A2(⌧) and WB = µ̂B1(⌧)  µ̂B2(⌧),
where µ̃j(⌧) =
R ⌧




for j = 1, 2. (ii) When Y (·) is continuously observed, a test statistics can be
constructed as
W̃ = µ̃1(⌧)  µ̃2(⌧),
where µ̃j(⌧) =
R ⌧
0 ŵ(u)ŜDj(u)r̃j(u)du. Let  ji and
b ji be straightforward mod-
ifications of  i and b i given in Theorem 3.2.1, and Uji and bUji be straightfor-
ward modifications of Ui and bUi given in Theorem 4.3.3. Theorem 3.4.1 states
the asymptotic distribution of the test statistics WA and WB under the null
hypothesis H0.
Theorem 3.4.1. Let ⇡̂j = nj/n be a consistent estimate of ⇡j, j = 1, 2.
Case with intermittently observed Y (·): With the regularity conditions
in Theorem 3.2.1 being satisfied for each group, under H0 : µ1(⌧) = µ2(⌧),
(n1n2/n)1/2WA and (n1n2/n)1/2WB converge in distribution to a zero-mean
normal random variable with variance ⇡2E { 1i(⌧)}2 + ⇡1E { 2i(⌧)}2. The
asymptotic variance can be consistently estimated by ⇡̂2 ·
Pn1
i=1




Case with continuously observed Y (·): With the regularity conditions
in Theorem 4.3.3 being satisfied for each group, under H0 : µ1(⌧) = µ2(⌧),
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(n1n2/n)1/2W̃ converges in distribution to a zero-mean normal random variable
with variance ⇡2E {U1i(⌧)}2 + ⇡1E {U2i(⌧)}2. The asymptotic variance can be
consistently estimated by ⇡̂2 ·
Pn1
i=1




Note that the test statistics WA, WB and W̃ estimate µ1(⌧)  µ2(⌧), which
can be interpreted as the weighted average di↵erence in ⌘j(t) = E{Yj1(t)I(Dj1  
t)} over the interval [0, ⌧ ], j = 1, 2. Consider the null hypothesis H 00 : ⌘1(t) =
⌘2(t) for all t 2 [0, ⌧ ] and the alternative that ⌘1(t)   ⌘2(t) for all t 2 [0, ⌧ ]
and ⌘1(·) 6= ⌘2(·). Then a natural statistics on which to base a test procedure
would be WA or W̃ . Testing H 00 based on WA or W̃ is a generalization of
the distance test in Pepe and Fleming (1989). When setting Yji(·) = 1 for
i = 1, . . . , nj and j = 1, 2, WA and W̃ reduce to the weighted Kaplan-Meier
statistic WKM =
R ⌧
0 ŵ(t){ŜD1(t)   ŜD2(t)}dt for testing the null hypothesis
H 000 : SD1(t) = SD2(t).
3.5 Simulation Studies
A series of simulation experiments are carried out to examine the finite-sample
properties of the proposed methods. In Section 3.5.1, when Y (·) is intermit-
tently observed, we examine the performance of µ̂A(t), µ̂B(t) for one-sample
estimation and WA,WB for two-sample test. In Section 3.5.2, when Y (·) is a
function of a recurrent event process and is continuously observed, we consider
the performance of test statistic W̃ with di↵erent choice of f .
3.5.1 Simulation when Y (·) is intermittently observed
In the following simulations, the association between D and Y (·) is induced
by a shared subject-specific random e↵ect Z, where Z is generated from a
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normal distribution with mean 0 and variance  21. Specifically, given Z, the
terminal event time D is generated from exponential distribution with rate
parameter   = a0 + (Z + k 1)2. Moreover, the longitudinal marker process is
generated from Y (t) = g(t) +Z + ✏(t); where the error term ✏(t) is a mean zero
Gaussian process with independent increments and a time-invariant variance
 22. Straightforward algebra gives E{Y (t) | D   t} = g(t)   2k 31t/(1 + 2 21t)
and P (D   t) = (1 + 2 21t)
 1/2 exp ( a0t  k2 21t/(1 + 2 21t)). Note that when
k = 0, surviors’ expected marker value E{Y (t) | D   t} is g(t), which is
the same as E{Y (t)}; moreover, the di↵erence between E{Y (t) | D   t} and
E{Y (t)} becomes larger as |k| increases. The model implies that subjects with
Z close to  k 1 have smaller rate parameter for the terminal event, and tend
to have longer survival time.
In our simulations for one-sample estimation, we set k = 1, a0 = 0.1,  1 =
0.5,  2 = 0.1, w(t) = 1, g(t) = t + 1. The censoring time is generated from
the uniform distribution on [0, 5]. The observation times are generated from
I(X   t)dN⇤(t) and N⇤(t) is a Poisson process with constant rate  ⇤(t) = 5.
We examine the performance of µ̂A(t) and µ̂B(t) when using the Epanechnikov
kernel with bandwidth h = n 1/3, n 2/5, as the regularity condition (A5) given
in the appendix is h = O(n ⌫), 1/4 < ⌫ < 1/2. We also consider leave-one-out
cross validation for choosing bandwidth as an extension of that for Nadaraya-
Watson estimator. The averaged square error (Härdle et al., 2004) is a com-
monly used criteria that measures how close the estimate r̂h is to the true curve





2dNi(u) in our case. We






r̂h, i(u) is the estimate for r(u) leaving out the ith observation, since minimizing
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Table 4.1 presents the summary statistics for µ̂A(t) and µ̂B(t) based on 2000
replications. The performances of the estimators are not sensitive to the choice
of bandwidth. As expected, the variances of the estimators increase as t in-
creases and decrease as sample size n increases. Our proposed procedure per-
forms well in finite-sample studies.
For two sample testing, we first consider scenarios that Y is observed at
intermittent time points. Suppose group 1 is the treatment group and group 2
is the control group, and the data of group 1 and 2 are generated from the one-
sample model above with di↵erent a0j,kj and gj(t) for jth group, j = 1, 2. We
consider the following five scenarios: (I) a01 = a02 = 0.1, k1 = k2 = 1, g1(t) =





1 + 2 21t exp{k2j 21t/(1 + 2 21t) 1}, j = 1, 2. (III) a01 = 0.1, a02 = 0.2, k1 =
k2 = 1, g1(t) = g2(t) = g(t). (IV) a01 = a02 = 0.1, k1 = k2 = 1, g1(t) =
g2(t) + 0.2, g2(t) = g(t). (V) a01 = 0.1, a02 = 0.2, k1 = k2 = 1, g1(t) = g2(t) +
0.2, gB(t) = g(t). The empirical powers of the proposed tests based on WA and
WB are summarized in Table 3.2, with nominal Type I error rate 0.05. We
also list the empirical power of the test based on the integrated di↵erence in
weighted Kaplan-Meier estimators as a reference, where the test statistics is
WKM =
R ⌧
0 w(t){ŜD1(t)  ŜD2(t)}dt. We set w(·) = 1 in our simulations.
For Scenario I, there is no di↵erence in the longitudinal marker process or
survival between group 1 and 2, thus null hypothesis H0 holds and the pro-
posed tests maintain the nominal Type I error rate. For Scenario II, group 1
performs better in terms of survival, while the summary measure of the two
groups are equal. Our proposed tests o↵er a criterion for decision-making and
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Table 3.1: Simulation summary statistics for µ̂A(t) and µ̂B(t)
µ̂A(t) µ̂B(t)
µ(t) Bias SE CP Bias SE CP SEE
n = 100, h = n 1/3
t = 1 1.076 0.016 0.062 0.932 0.015 0.061 0.938 0.061
t = 2 2.274 0.011 0.155 0.946 0.014 0.155 0.946 0.157
t = 3 3.540 0.001 0.302 0.948 0.014 0.301 0.945 0.301
n = 100, h = n 2/5
t = 1 1.076 0.008 0.062 0.943 0.009 0.061 0.945 0.061
t = 2 2.274 0.002 0.155 0.948 0.009 0.155 0.947 0.156
t = 3 3.540 0.011 0.302 0.944 0.009 0.301 0.944 0.300
n = 100, data-adaptive bandwidth
t = 1 1.076 0.008 0.061 0.938 0.007 0.060 0.948 0.060
t = 2 2.274 0.003 0.160 0.936 0.008 0.161 0.936 0.156
t = 3 3.540 0.004 0.301 0.946 0.010 0.301 0.944 0.301
n = 200, h = n 1/3
t = 1 1.076 0.010 0.044 0.934 0.010 0.043 0.936 0.043
t = 2 2.274 0.008 0.111 0.945 0.010 0.112 0.944 0.111
t = 3 3.540 0.001 0.220 0.946 0.007 0.220 0.949 0.215
n = 200, h = n 2/5
t = 1 1.076 0.005 0.044 0.938 0.006 0.043 0.946 0.043
t = 2 2.274 0.002 0.112 0.942 0.006 0.112 0.944 0.111
t = 3 3.540 0.007 0.220 0.945 0.004 0.220 0.948 0.214
n = 200, data-adaptive bandwidth
t = 1 1.076 0.003 0.045 0.938 0.003 0.044 0.942 0.043
t = 2 2.274 0.001 0.116 0.942 0.003 0.116 0.941 0.111
t = 3 3.540 0.006 0.222 0.939 0.004 0.222 0.940 0.215
Note: Bias is the empirical bias; SE is the empirical standard error; SEE is the empirical
mean of the standard error estimates, and the two estimators have the same SEE; CP is the
empirical coverage probability of the 95% confidence interval.
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still maintain the nominal Type I error rate. For Scenario III, IV and V, there
is no conflict of treatment e↵ects on longitudinal marker process and time to
terminal event, and group 1 performs better than group 2. Tests based on WA
or WB can be viewed as testing the existence of treatment e↵ect using synthe-
sized information from both longitudinal marker process and survival outcome,
while test based on WKM can be viewed as testing the existence of treatment
e↵ect using only survival outcome. For Scenario III, there is only a di↵erence
in survival outcome between two groups, the proposed tests and the test based
on comparing integrated di↵erence in survival function have similar powers in
detecting treatment e↵ect. For scenario IV and V, taking into account the longi-
tudinal marker process helps to increase the power of detecting treatment e↵ect
and make correct decisions.
Table 3.2: Empirical power of two-sample test when Y (·) is intermittently ob-
served
n1 = n2 = 100 n1 = n2 = 200
Scenario WA WB WKM WA WB WKM
I 0.04 0.04 0.05 0.05 0.05 0.05
II 0.05 0.05 0.45 0.05 0.04 0.75
III 0.18 0.19 0.18 0.32 0.32 0.30
IV 0.22 0.23 0.05 0.35 0.34 0.05
V 0.53 0.55 0.17 0.83 0.84 0.28
3.5.2 Simulation when Y (·) is continuously observed
We also consider the scenario where we have a recurrent event process with a
terminal event. Suppose Z ⇠ Gamma(↵,↵) is the subject-specific random ef-
fect. For the jth group, the recurrent event process is generated from a Poisson
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process with rate parameter Zcj, and the terminal event time follows exponen-
tial distribution with rate parameter Zdj. Note that larger ↵ indicates that
the two event processes are less correlated, and when ↵ = 1, the two event
processes are independent. We consider the following five scenarios: (VI) ↵ = 4,
d1 = d2 = 0.2, c1 = c2 = 2. (VII) ↵ = 1, d1 = d2 = 0.2, c1 = c2 = 2. (VIII)
↵ = 4, d1 = 0.2, d2 = 0.3, c1 = c2 = 2. (IX) ↵ = 4, d1 = d2 = 0.2, c1 = 2, c2 = 3.
(X) ↵ = 4, d1 = 0.2, d2 = 0.3, c1 = 2, c2 = 3. Table 3.3 presents the empirical
power of the proposed tests in Section 3.5 using di↵erent pre-specified functions
f : (a) f1(x) = (3 x)I(x  3)+1, (b) f2(x) = 0.8x, (c) f3(x) = I(x  1). Note
that and f3 corresponds to the composite endpoint approach (Meinert, 2012).
The empirical powers are summarized in Table 3.3. For Scenario VI and VII,
group 1 and group 2 have equal summary measure, and the tests maintain the
nominal Type I error rate 0.05. For Scenario VIII, IX and X, group 1 performs
better than group 2, and we are interested in the power of the three tests in
detecting treatment e↵ect. Tests using f1 and f2 have similar powers. However,
the test using f3 does not perform well in Scenario IX, since the composite event
is very likely to be the first recurrent event and the recurrent event processes of
group 1 and 2 follow the same distribution. Moreover, the composite endpoint
approach is not as powerful as the other two test in Scenario X.
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Table 3.3: Empirical power of two-sample test where Y (·) is a function of re-
current event process
n1 = n2 = 100 n1 = n2 = 200
Scenario f1 f2 f3 f1 f2 f3
VI 0.04 0.05 0.05 0.06 0.05 0.05
VII 0.05 0.04 0.06 0.05 0.05 0.05
VIII 0.45 0.52 0.46 0.76 0.83 0.75
IX 0.14 0.16 0.05 0.27 0.30 0.05
X 0.75 0.80 0.52 0.96 0.98 0.81
3.6 Proofs
3.6.1 Proof of Theorem 3.2.1 and 3.2.2
Assumptions (A1)-(A5) are the regularity conditions in Theorem 3.2.1:
(A1) The censoring time Ci is independent of {Di, N⇤i (·), Yi(·)} and P (Xi  
⌧) > 0.
(A2) The marker process Yi(t) is bounded.
(A3) The counting process N⇤i (·) is independent of {Di, Ci, Yi(·)}. The obser-
vation time process I(Xi   t)N⇤i (t) is bounded and the second derivative
of its rate function  (t) is bounded. Moreover,  (t) > 0 on [0, ⌧ ].
(A4) Define ⇠(t) such that ⇠(t)dt = E[Y (t)I(X   t)dN⇤(t)], the second deriva-
tive of ⇠(t) is bounded on [0, ⌧ ].
(A5) K(·) is a symmetric kernel function with bounded support and bounded
variation, and h = O(n ⌫), 1/4 < ⌫ < 1/2.
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We first present two technical lemmas used in the proof. Lemma 3.6.1 states
the uniform consistency of the proposed kernel-type estimators, and Lemma
3.6.2 is used when deriving the i.i.d. representation of µ̂A and µ̂B. The two
lemmas are proved later in Section 3.6.3 and 3.6.4.






Kh(t  u)Yi(u)I(Xi   u)dN⇤i (u)
for t 2 [h, ⌧   h], ⇠̂h(t) = ⇠̂h(h) for t 2 [0, h) and ⇠̂h(t) = ⇠̂h(⌧   h) for t 2
(⌧   h, ⌧ ]. Then for t 2 [0, ⌧ ], ⇠̂h(t),  ̂h(t) and r̂h(t) uniformly converge in
probability to ⇠(t),  (t) and r(t), respectively.



























Yi(u)I(Xi   u)dN⇤i (u) + op(1).













































is the Nelson-Aalen estimator, where NDi (u) = I(Di  u, i = 1). By the












n{⇤̂D(u)  ⇤D(u)}dµ(u) + op(1).












 1dMDi (u) + op(1),




0 I(Xi   u)d⇤D(u). By the uniform consistency of  ̂h
and Lemma 2, and following similar steps as Mammen and Nielsen (2007), the

















Yi(u)I(Xi   u)dN⇤i (u) 
p
nµ(t) + op(1).



























































0 E[Y (u)I(X   u)dN
⇤(u)] and R̂(t) =
R t
0 Ê[Y (u)I(X   u)dN
⇤(u)],
where Ê[Y (u)I(X   u)dN⇤(u)] = 1/n
Pn
i=1 Yi(u)I(Xi   u)dN⇤i (u). By the
uniform consistency of  ̂h and asymptotic equivalence of ŜD and e ⇤̂
D
, the first


















Yi(u)I(Xi   u)dN⇤i (u) 
p
nµ(t) + op(1).




n{⇤̂D(u) ⇤D(u)}dµ(u)+op(1). And by the






























i=1 i(t) + op(1). Since  i(t) can be written





n{µ̂A(t) µ(t)} holds. The consistency
of the variance estimates 1/n
Pn
i=1
b i(s)b i(t) follows from the arguments used
in the proof of Lin et al. (1998).
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3.6.2 Proof of Theorem 3.3.1 and comparison of asymp-
totic variance of µ̂A(t) and µ̃(t)










i=1 Yi(u)I(Xi   u)
n 1
Pn










i=1 Yi(u)I(Xi   u)
n 1
Pn
i=1 I(Xi   u)
  E{Y (u)I(X   u)}
n 1
Pn









E{Y (u)I(X   u)}
n 1
Pn
i=1 I(Xi   u)




Similar as the proof for Theorem 3.2.1, we have
p






















SD(u)E{Y (u)I(X   u)}
SX(u)2


































We now prove thatE{ i(t)2}   E{Ui(t)2}. Taking fi(u) = SD(u)[SX(u)Yi(u)I(Xi  





and Ui(t) = Ai(t)+
R t





































































































Therefore we prove that the asymptotic variance of µ̃(t) is smaller than that of
µ̂A(t) and µ̂B(t).
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3.6.3 Proof of Lemma 3.6.1






























|R̂2(t) R2(t)| · V (K).
where V (K) is the variation of the kernel function K. The functions R2i(t) =
R t
0 Yi(u)I(Xi > u)dN
⇤
i (u) are monotone and bounded, therefore have pseudodi-
mension at most 1. From Pollard (1990) p.37, supt2[0,⌧ ]
p
n | R̂2(t) R2(t) | has




n | R̂2(t) R2(t) |> t) < e Ct
2
.





| R̂2(t) R2(t) |> ✏) = P ( sup
t2[0,⌧ ]
p
























and supt2[0,h] | ⇠(t)   ⇠(h) |= O(h), supt2[⌧ h,⌧ ] | ⇠(t)   ⇠(⌧   h) |= O(h).
Therefore, the uniform consistency holds. Given the uniform consistency for  ̂h
and ⇠̂h, r̂h uniformly converges in probability to r on [0, ⌧ ].
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3.6.4 Proof of Lemma 3.6.2
















0 Kh(t  u)dNi(u) for t 2 [h, ⌧   h], i(t) =  i(h) for t 2 [0, h),
and  i(t) =  i(⌧   h) for t 2 (⌧   h, ⌧ ]. Then  ̂h(t) =
Pn
i=1  i(t). We the above
equation under four scenarios (a) 0 < s  h, (b) h < s  3h, (c) 3h < s  ⌧  h
and (d) ⌧   h < s  ⌧ .




















































0 dNi(u)}] converge weakly to a Gaussian process





































































































= ⇧1 + ⇧2 + ⇧3.
We then prove E(⇧1+⇧2+⇧3) = O(h2). By Equation (3.6.3), we have E(⇧1) =
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= O(h2) +O(h2) = O(h2).









































0 dNi(u)} = O(h












 2  M2h, where M2 is a constant. Then

















































=⇧1 + ⇧2 + ⇧3.






0 dNi(u)} = O(
p
nh2) + op(1).


































































⌧ h  i(⌧   h)dt  
R s
⌧ h dNi(u) = O(h







0 dNi(u)} = O(
p
nh2)+ op(1) also holds.

























u)dN⇤i (u) + op(1) is proved by changing dNi(·) to Yi(·)dNi(·).
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Chapter 4
Recurrent Marker Process in the
Presence of Competing Terminal
Events
4.1 Recurrent Marker Processes
Let {N(t), t   0} be a recurrent event process with N(t) representing the total
number of recurrent events occurring at or prior to t. Suppose the occurrence
of a recurrent event at t, i.e., dN(t) = 1, is marked by a measurement Y (t), and
for ease of discussion, we assume that Y (t) is nonnegative. Then, Y (t) can be
considered as a marker measurement for the recurrent event occurring at t, and
we represent the marked recurrent event process by {N(t), Y (t)|dN(t)=1; t   0}.
Consider the case where a terminal event is present, and the marked recur-
rent event process {N(t), Y (t)|dN(t)=1; t   0} vanishes after the terminal event.
Specifically, in situations where the marker Y (·) is a utility measurement such
as medical cost or length of stay in hospital, the main interest would natu-
rally be the utility consumed by survivors in the population. Let the time
to a terminal event be represented by D, which is possibly correlated with
{N(t), Y (t)|dN(t)=1; t   0}, then the stochastic process {Y (t)dN(t), 0  t  D}
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is frequently of interest.
In the presence of a terminal event without competing risks, the recurrent




Y (u)I(D > u)dN(u), (4.1.1)
and we use the superscript “total” to distinguish (4.1.1) from recurrent marker
processes under competing risks model, which is defined later in this section.
The mean function (MF) is defined as




Y (u)I(D   u)dN(u)
 
.
When Y (·) is a utility measure, the MF  (t) corresponds to the average of
cumulative utility consumed before the terminal event during time interval [0, t],
which is the utility of real life in case death is the terminal event. Also note
that by setting Y (·) = 1, the recurrent marker process reduces to recurrent
event process and M total(t) = N(min(D, t)). Define  (t) as the derivative of
 (t), that is, d (t) = E{Y (t)I(D   t)dN(t)} =  (t)dt. The function  (t) is
the rate of change of the MF at time t, which can be regarded as a counterpart
of the rate function for a recurrent event process.
Now further consider recurrent marker process in the presence of a terminal
event with competing risks. Suppose the occurrence of the terminal event is
caused by one of J di↵erent types of risks, where the risk-type indicator is
denoted by ⇧ 2 {1, . . . , J}. Let ⌧ be a pre-specified constant; for example, ⌧
could be the maximum length of follow-up time or the length of time where
investigators in a research project wish to study the recurrent marker process.
For practical consideration, due to limited follow-up time, subjects with D < ⌧
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are classified according to the original risk-type of terminal event ⇧ = j (j =
1, . . . , J), and subjects with D   ⌧ are classified into the last category of risk-
type, J + 1. In applications, subjects of risk-type J + 1 can be thought of as
those “long-term survivors”or “cured cases”.
For 0  t  ⌧ and j = 1, 2, . . . , J , the recurrent marker process with type-j




Y (u)I(⇧ = j, u  D < ⌧)dN(u),




Y (u)I(D   ⌧)dN(u).
Taking expectation of Mj(t), the type-j MF at time t is
 j(t) = E{Mj(t)}, j = 1, 2, . . . , J + 1.
For j = 1, 2, . . . , J +1, the MF  j(t) is the expectation of cumulative recurrent
marker prior to time t attributed to type-j risk. To connect the function  (t)






In practice, another quantity of interest is the conditional mean function of
recurrent marker process given risk-type j, that is,
 cj(t) =
(
E{M total(t) | ⇧ = j,D  ⌧} j = 1, . . . , J,
E{M total(t) | D   ⌧} j = J + 1.
Note that  cj(t) is the expectation of cumulative recurrent marker up to time t
of subpopulation with type-j risk. We shall consider nonparametric estimation
of  (t),  j(t) and  cj(t) (j = 1, . . . , J + 1) in later sections.
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4.2 Nonparametric Estimation in Non-Competing
Risks Model
We first consider nonparametric estimation of  (t) without the complication
of competing risks. In practice, the terminal event time D is subject to right
censoring due to study end or premature dropout, and the recurrent marker
process cannot be observed after censoring. We denote the censoring time by
C and assume that C is independent of {D, Y (t)dN(t); 0  t  ⌧}. The
observed terminal event time is X = min(D,C) with a censoring indicator
  = I(D < C). The observed data {Xi, i, Yi(t)I(Xi   t)dNi(t), I(Xi  
t)Ni(t) : 0  t  ⌧, i = 1, . . . , n} are assumed to be independent replicates of
{X, , Y (t)I(X   t)dN(t), I(X   t)N(t) : 0  t  ⌧}.
Let SD(·) be survival function of the terminal event time D. Under the
independent censoring assumption, subjects in the risk set at time u are a rep-
resentative sample of event-free individuals at time u in the target population,
and we note that
 (u)du = SD(u) · E{Y (u)dN(u)| D   u} = SD(u) · E{Y (u)dN(u)| X   u}.




SD(u) · E{Y (u)dN(u) | X   u}. (4.2.1)
To estimate  (t), one can use the moment estimator of E{Y (u)dN(u) | X   u}
based on subjects in the risk set {i : Xi   u} and estimate SD(u) by the







i=1 Yi(u)I(Xi   u)dNi(u)
Pn
i=1 I(Xi   u)
. (4.2.2)
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The estimator in (4.2.2) can be viewed as an extension of the nonparametric
estimator of mean frequency function in Ghosh and Lin (2000), where the special
case Y (·)|dN(·)=1 = 1 was considered. To study large sample properties of  ̂(t),
the following notations are introduced. Let SC and ⇤C be the survival function
and cumulative hazard function of the censoring time C, respectively; and let
SX denote the survival function of the observed failure time X. We then define
NCi (t) = I(Ci  t, i = 0) and MCi (t) = NCi (t)  
R t
0 I(Xi   u)d⇤C(u).
Theorem 4.2.1 summarizes the asymptotic property of  ̂(t), with proof given in
Appendix 4.6.1.
Theorem 4.2.1. Under Assumption (A1) and (A2) in Appendix, for t 2 (0, ⌧ ],
the stochastic process n1/2{ ̂(t)    (t)} has an asymptotically i.i.d. represen-
tation n1/2{ ̂(t)   (t)} = n 1/2
Pn















Moreover, as n ! 1, n1/2{ ̂(t)   (t)} converges weakly to a zero-mean tight
Gaussian process whose covariance function at (t1, t2) can be consistently esti-
mated by n 1
Pn
i=1 âi(t1)âi(t2) for t1, t2 2 (0, ⌧ ], with âi(t) defined in Appendix
4.6.1.










Kh(t  u)Yi(u)I(Xi   u)dNi(u),
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where Kh(x) = h 1K(x/h) is a kernel function with bandwidth h, with K(·)
satisfing
R 1
 1 K(x)dx = 1 and
R 1
 1 xK(x)dx = 0. Note that  ̂h(t) can be viewed
as an extension of the kernel-type estimator proposed by Wang and Chiang
(2002).
4.3 Nonparametric Estimation in Competing
Risks Model
When the terminal event occurs with competing risks, nonparametric estimation
of the MF will need to take into account the data structure that the risk-type
indicator, ⇧, is available only when the terminal event is observed. Under
competing risks model, the censoring time C is assumed to be independent
of {D,⇧, Y (t)dN(t); 0  t  ⌧}. The observed data {Xi, i,⇧i, Yi(t)I(Xi  
t)dNi(t), I(Xi   t)Ni(t) : 0  t  ⌧, i = 1, . . . , n} are assumed to be indepen-
dent replicates of {X, ,⇧, Y (t)I(X   t)dN(t), I(X   t)N(t) : 0  t  ⌧}.








SD(u) E{I(⇧ = j)Y (u)dN(u) | X   u}  SD(⌧)E{I(⇧ = j)M total(t) | X   ⌧}.
Therefore, for j = 1, . . . , J , along the same line of the estimator  ̂(t) in (4.2.2),
a hypothetical estimator of  j(t) that utilizes the recurrent marker history data






i=1 I(Xi   u,⇧i = j)Yi(u)dNi(u)
Pn
i=1 I(Xi   u)
  ŜD(⌧)
Pn
i=1 I(Xi   ⌧,⇧i = j)M totali (t)
Pn
i=1 I(Xi   ⌧)
. (4.3.1)
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And for risk type J + 1, an estimator of  J+1(t) = SD(⌧)E{M total(t) | X   ⌧}
can be constructed as
 ̂HJ+1(t) = ŜD(⌧)
Pn
i=1 I(Xi   ⌧)M totali (t)
Pn
i=1 I(Xi   ⌧)
.
Clearly, the estimator  ̂Hj (t) (j = 1, . . . , J) depends on data information of ⇧
from all subjects in the risk set at the observed recurrent event times. In reality,
however, knowledge of ⇧ is rarely available from subjects whose terminal event
are censored (  = 0), therefore the hypothetical estimator in (4.3.1) fails to
serve as a proper estimator for most of the applications. We next propose an
estimation approach which is useful for commonly encountered recurrent marker
data with competing terminal events.
For di↵erent risk types j = 1, . . . , J , we define Hj(t,m, u) = Pr(⇧ =
j,M total(t)  m,D  u). With straightforward algebra, the mean function





Note that for u 2 [0, ⌧ ], Hj(t,1, u) = Pr(⇧ = j,D  u) is the cumulative inci-
dence function in standard competing risks model (Prentice et al., 1978; Gray,
1988; Fine and Gray, 1999). Define Uj(t,m, u) = Pr(⇧ = j,M total(t)  m,  =
1, X  u). Under the assumption that C is independent of {D,⇧, Y (t)dN(t); 0 














where SX is the survival function of the observed failure time X. Note that
when a terminal event is uncensored, the risk type is observed and therefore
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Uj(t,m, u) can be estimated by its empirical average, that is, Ûj(t,m, u) =
n 1
Pn
i=1 I(⇧i = j,M
total
i (t)  m, i = 1, Xi  u). By plugging into the
Kaplan-Meier estimate ŜD and the empirical estimates (ŜX , Ûj), Hj(t,m, u)












mĤj(t, dm, ⌧). (4.3.3)
and  J+1(t) is still estimated by
 ̂J+1(t) ⌘  ̂HJ+1(t) = ŜD(⌧)
Pn
i=1 I(Xi   ⌧)M totali (t)
Pn
i=1 I(Xi   ⌧)
.
Theorem 4.3.1 summarizes the large-sample properties of  ̂j(t), j = 1, . . . , J+
1, with proof given in Appendix 4.6.2.
Theorem 4.3.1. Under Assumption (A1’) and (A2) in Appendix, for t 2 (0, ⌧ ]
and j = 1, . . . , J +1, the stochastice process n1/2{ ̂j(t)  j(t)} has an asymp-
totically i.i.d representation n1/2{ ̂j(t)    j(t)} = n 1/2
Pn
i=1 bji(t) + op(1),
where for j = 1, . . . , J ,
bji(t) =M
total








E{I(⇧ = j,D  u)M total(t)}SX(u) 1dMCi (u),
and for j = J + 1,






Moreover, as n ! 1, n1/2{ ̂j(t)  j(t)} converges weakly to a zero-mean tight
Gaussian process with covariance function E{bj1(t1)bj1(t2)} for t1, t2 2 (0, ⌧ ],
and the covariance can be consistently estimated by n 1
Pn
i=1 b̂ji(t1)b̂ji(t2), with
b̂ji(t) defined in Appendix 4.6.2.
4.4 Improved Estimation in Competing Risks
Model
As the estimator  ̂j(t) utilizes marker information only from uncensored sub-
jects, the estimation may be ine cient when censoring is heavy; in contrast, for
the estimation of  (t), the estimator  ̂(t) in Section 3.1 utilizes marker history
data from both censored and uncensored subjects. Thus, it is of no surprise that
 ̂(t) is more e cient than
PJ+1
j=1  ̂j(t) for estimating  (t). When formulating
estimators for type-j MF  j(t), a question arises as to whether it is possible to
borrow information from  ̂(t) to improve the estimation of  j(t).






In general,  ̃j(t) may or may not be more e cient than  ̂j(t), even though
the former estimator involves marker information from both censored and un-
censored subjects and the latter only uses marker information from uncen-
sored ones. In what follows, we propose an estimator that is more e cient
than  ̃j(t) and  ̂j(t). We consider a class of linearly combined estimators
Wjt = {wjt ̂j(t) + (1   wjt) ̃j(t) : wjt 2 R} and propose the use of the most
e cient estimator from this class. Let  ̄j(t) = wjt ̂j(t) + (1   wjt) ̃j(t) be a
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weighted average of  ̂j(t) and  ̃j(t). Clearly,  ̂j(t) and  ̃j(t) both belong to
Wjt. Using results from Theorem 4.2.1 and 4.3.1, estimators in Wjt are consis-
tent and asymptotically normal. Thus, a question of interest is to identify the
estimator in Wjt which has the minimal asymptotic variance.
To study the asymptotic variance of the estimators inWjt, we define⌃j(t1, t2) =
{ jpq(t1, t2)}2⇥2 for t1, t2 2 [0, ⌧ ], where  j11(t1, t2),  j12(t1, t2),  j21(t1, t2) and


















n{ ̃j(t2)   j(t2)}], respectively. We fur-
ther assume that ⌃j(t, t) is a nonsingular matrix for t 2 (0, ⌧ ]. Define the
vector wjt = (wjt, 1 wjt)T, then the asymptotic variance of
p
n{ ̄j(t)  j(t)}
iswTjt⌃j(t, t)wjt. We consider the optimization of asymptotic variance to obtain









where we define e = (1, 1)T. And using this optimal weight w⇤jt, the asymptotic
variance of
p
n{ ̄j(t)    j(t)} is {eT⌃j(t, t) 1e} 1. By the Cauchy-Schwartz
inequality, for any weight wjt, we have
{wTjt⌃j(t, t)wjt}{eT⌃j(t, t) 1e}   (wTjte)2 = 1,
or equivalently,
wTjt⌃j(t, t)wjt   {eT⌃j(t, t) 1e} 1. (4.4.1)
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Thus, in the classWjt, using the weightw⇤jt results in the estimator with smallest
asymptotic variance. In real applications, the optimal w⇤jt involves ⌃j(t, t),
which is unknown and needs to be estimated from data. By applying the results
of Theorem 4.2.1 and 4.3.1, we can consistently estimate ⌃j(t, t) by b⌃j(t, t),
with details given in the Appendix 4.6.3. We propose the following improved
estimator for  j(t),
 ̂impj (t) = ŵ
⇤
jt ̂j(t) + (1  ŵ⇤jt) ̃j(t), (4.4.2)
where ŵ⇤jt = (ŵ
⇤
jt, 1  ŵ⇤jt)T = b⌃j(t, t) 1e/eT b⌃j(t, t) 1e. Here we indicate that
the estimator using the estimated weight ŵ⇤jt possesses the same e ciency as the
estimator with w⇤jt as the weight. Theorem 4.4.1 summarizes the large-sample
properties of  ̂impj (t) and the proof is given in Appendix 4.6.3.
Theorem 4.4.1. Under Assumption (A1’),(A2) and (A3) in Appendix, for
j = 1, . . . , J + 1,
p
n{ ̂impj (t)    j(t)}(0 < t  ⌧) converges weakly to a zero-
mean tight Gaussian process with
eT⌃j(t1, t1) 1⌃j(t1, t2)⌃j(t2, t2) 1e
eT⌃j(t1, t1) 1eeT⌃j(t2, t2) 1e
as the covariance function at (t1, t2) for t1, t2 2 (0, ⌧ ], and the covariance can be
consistently estimated by n 1
Pn
i=1 f̂ji(t1)f̂ji(t2), with f̂ji(t) defined in Appendix
4.6.3.
Clearly, the result of Theorem 4.1 implies that the asymptotic variance of
p






In real data applications, it would also be of interest to estimate the mean
recurrent marker process within each risk group,  cj(t). For j = 1, . . . , J , since
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where Ĥj(0,1, ⌧) is defined in equation (4.3.2). For risk-type j = J + 1, since





Corollary 4.2 summarizes the large-sample properties of  ̂cj(t), with proof given
in Appendix 4.6.4.
Corollary 4.4.2. Under Assumption (A1’),(A2) and (A3) in Appendix, for
j = 1, . . . , J + 1, the stochastic process n1/2{ ̂cj(t)    cj(t)}(0 < t  ⌧) con-
verges weakly to a zero-mean tight Gaussian process with covariance function
E{gj1(t1)gj1(t2)} for t1, t2 2 (0, ⌧ ], and the covariance function can be con-
sistently estimated by n 1
Pn
i=1 ĝji(t1)ĝji(t2), with ĝji(t) defined in Appendix
4.6.4.
4.5 Simulation Studies
A series of simulation experiments are carried out to examine finite-sample per-
formance of the proposed methods. We simulate the data so that the association
among the random variables {D, Y (·)|dN(·)=1, N(·),⇧} is induced by a subject-
specific random e↵ect Z, where Z is generated from a gamma distribution with
shape parameter ↵ = 2 and rate parameter   = 0.5. Specifically, given Z, the
terminal event time D is generated from Weibull distribution with rate param-
eter .01 ⇥ Z and shape parameter ⌫ = 3; the recurrent event process N(·) is a
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Poisson process with rate function  (t) = I(Z > z0)+1, where z0 is the median
of Z; and the marker process is generated from Y (t)|dN(t)=1 = 1 + t+ Z + ✏(t);
where the error term ✏(t) is a mean zero Gaussian process with independent
increments and a time-invariant standard deviation   = 0.1. We assume there
are two types of terminal event, and that the cause of death is determined by
Z: we set ⇧ = 1 when Z  z0 and set ⇧ = 2 when Z > z0. Moreover, we set
⌧ = 5, and subjects with D > 5 belong to the third risk type. The censoring
time C is generated from Uniform[0, 19] to produce a 25% censoring rate. We
set the sample size n = 200 and n = 400. The simulation results are based on
2000 replications and are summarized in Table 1.
It can be seen that the proposed estimators  ̂j,  ̃j and  ̂
imp
j all perform
well with moderate sample sizes. In our simulation, note that  ̂j has smaller
standard error than  ̃j for j = 1, 3, while the standard error of  ̃2 outperforms
that of  ̂2. In whichever case, the improved estimator  ̂
imp
j is either more
e cient than or as e cient as  ̂j and  ̃j. And, as expected, the standard error
of the proposed estimators increase with time and decrease with sample size.
4.6 Proofs
We first introduce a few regularity conditions used in the theorems:
(A1) The censoring time C is independent of {D, Y (t)dN(t); t 2 [0, ⌧ ]} and
P (X   ⌧) > 0.
(A1’) The censoring time C is independent of {D, Y (t)dN(t),⇧; t 2 [0, ⌧ ]} and
P (X   ⌧) > 0.
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Table 4.1: Simulation summary statistics for  ̂impj ,  ̂j and  ̃j
 ̂impj  ̂j  ̃j
Bias SE SEE CP Bias SE Bias SE
n = 200
 1(t) t = 1 0.001 0.095 0.093 0.935 0.002 0.095 0.004 0.152
t = 2 0.003 0.189 0.185 0.937 0.005 0.189 0.011 0.277
t = 3 0.002 0.297 0.291 0.939 0.002 0.297 0.006 0.406
 2(t) t = 1 0.014 0.307 0.298 0.936 0.004 0.324 0.002 0.308
t = 2 0.020 0.589 0.587 0.946 0.008 0.613 0.002 0.590
t = 3 0.021 0.893 0.889 0.941 0.012 0.924 0.008 0.895
 3(t) t = 1 0.012 0.175 0.170 0.932 0.003 0.179 0.006 0.197
t = 2 0.020 0.355 0.349 0.932 0.003 0.361 0.008 0.384
t = 3 0.028 0.587 0.575 0.928 0.001 0.595 0.005 0.617
n = 400
 1(t) t = 1 0.001 0.067 0.066 0.947 0.001 0.067 0.000 0.109
t = 2 0.001 0.131 0.132 0.947 0.001 0.131 0.003 0.199
t = 3 0.001 0.206 0.207 0.948 0.002 0.207 0.005 0.291
 2(t) t = 1 0.006 0.211 0.212 0.951 0.003 0.221 0.004 0.211
t = 2 0.012 0.420 0.417 0.946 0.003 0.438 0.002 0.420
t = 3 0.010 0.644 0.630 0.943 0.010 0.664 0.007 0.646
 3(t) t = 1 0.003 0.121 0.122 0.949 0.001 0.123 0.002 0.138
t = 2 0.006 0.249 0.250 0.945 0.003 0.253 0.001 0.272
t = 3 0.014 0.411 0.410 0.945 0.002 0.418 0.002 0.433
Note: Bias is the empirical bias; SE is the empirical standard error; SEE is the empirical
mean of the standard error estimates; CP is the empirical coverage probability of the 95%
confidence interval.
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(A2) The stochastic process N(t) and Y (t)dN(t) are bounded for t 2 [0, ⌧ ].
(A3) The covariance matrix ⌃j(t, t) is nonsingular for t 2 (0, ⌧ ].
4.6.1 Proof of Theorem 4.2.1
Assumptions (A1) and (A2) are the regularity conditions for Theorem 4.2.1.
Define NCi (t) = I(Ci  t, i = 0), we consider Nelson-Aalen estimator for the












where ŜX(t) = n 1
Pn
i=1 I(Xi   t) is the empirical estimator for SX(t). Note
that SC(t) can be estimated by e ⇤̂C(t), which is asymptotically equivalent to
the Kaplan-Meier estimator. We use ŜC(t) = e ⇤̂C(t) in what follows. For























0 Yi(u)I(Xi > u)dNi(u); By the martingale central limit theorem, we
have
p







 1dMCi (u) + op(1),
where MCi (t) = NCi (t) 
R t
0 I(Xi   u)d⇤C(u).
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Given the estimator  ̂(t) =
R t
0 e
⇤̂C(u)dB̂(u), by the functional delta method
(van der Vaart, 2000; Theorem 20.8, Lemma 20.10), the functional (F1, F2) 7!
R t
0 e
F1dF2 is Hadamard-di↵erentiable as a map into the set of cadlag functions



























































The limiting covariance function at (t1, t2) is E{a1(t1)a1(t2)}, which can
be consistently estimated by n 1
Pn
i=1 âi(t1)âi(t2) where âi(t) is obtained by
replacing all the unknown parameters in ai(t) with their respective empirical
estimators. The consistency of the variance estimator can be proved using
arguments similar to, for example, the proof of Theorem 3 of Lin et al. (1998).
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4.6.2 Proof of Theorem 4.3.1
Assumptions (A1’) and (A2) are the regularity conditions for Theorem 4.2.1.
We first consider the large sample properties for  ̂j(t), j = 1, . . . , J . By straight-






























whereND(t) = I(D  t,  = 1), and Ĝj(u, t) = n 1
Pn
i=1 I(⇧i = j)M
total
i (t)NDi (u)








E{I(⇧ = j)M total(t)dND(u)}
SC(u)
= E[I(⇧ = j)M total(t)I(D  ⌧)E
 
 SC(D)
 1 | D,M total(t),⇧
 
]
= E{I(⇧ = j)M total(t)I(D  ⌧)}
=  j(t).




from the domain D[0, ⌧ ]⇥BVM [0, ⌧ ]2 to D[0, ⌧ ], where BVM [0, ⌧ ]2 means the set
of cadlag functions F4 : [0, ⌧ ]⇥ [0, ⌧ ] 7! [0,M ] with supt2[0,⌧ ]
R ⌧
0 |F4(du, t)| < M .
SinceM total(t) is increasing with t andND(u) is increasing with u, the functional
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class {I(⇧ = j)M total(t)ND(u), t, u 2 [0, ⌧ ]} is Donsker by Lemma 4.1 and
Corollary 9.32 in Kosorok (2007). Thus, the stochastic process
p
n{Ĝj(u, t)  
Gj(u, t)} converges weakly to a Gaussian process. Applying techniques simi-
lar to Lemma 20.10 in van der Vaart (2000), the functional (F3(u), F4(u, t)) 7!
R ⌧
0 e





















































I(Xi   ⌧)M totali (t)
SC(⌧)



















I(Xi   ⌧)M totali (t)
SC(⌧)














bJ+1,i(t) + op(1) .
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For j = 1, . . . , J + 1, note that the stochastic process bj(t) (0 < t  ⌧) has zero
mean and can be written as the sum of monotone cadlag processes and is there-
fore Donsker (Lemma 4.1, Kosorok (2007)). We then have n 1/2
Pn
i=1 bji(t) (0 <
t  ⌧) converges weakly to a tight and zero-mean Gaussian process. Again, the
variance-covariance function can be consistently estimated by n 1
Pn
i=1 b̂ji(t1)b̂ji(t2),
where b̂ji(t) is obtained by replacing all the unknown parameters in bji(t) with
their respective empirical estimators. Specifically, for j = 1, . . . , J , the estima-






4.6.3 Proof of Theorem 4.4.1
Assumptions (A1’), (A2) and (A3) are the regularity conditions for Theorem
4.4.1. We first derive the optimal weight function. Consider the Lagrange
function defined by
V (wjt, k) = w
T
jt⌃j(t, t)wjt + k(w
T
jte  1).








jte  1 = 0
And solving the equations gives us
(




Together with the inequality, we know that w⇤jt ⌘ (w⇤jt, 1   w⇤jt)T =
⌃j(t,t) 1e
eT⌃j(t,t) 1e























to estimate ⌃j(t1, t2), and use ŵ⇤jt =
b⌃j(t,t) 1e
eT b⌃j(t,t) 1e
to estimate the optimal weight
w⇤jt.
To obtain the i.i.d. representation of  ̂impj (t), we have
p


















It’s easy to see that
p
n{ ̂impj (t)  j(t)} (0 < t  ⌧) converges weakly to a tight
and zero-mean Gaussian process. The covariance at (t1, t2) can be consistently
estimated by n 1
Pn
i=1 f̂ji(t1)f̂ji(t2), where f̂ji(t) = ŵ
⇤
jtb̂ji(t) + (1  ŵ⇤jt){âi(t) 
P
k 6=j b̂ki(t)}.
4.6.4 Proof of Corollary 4.4.2
We assume Hj(0,1, ⌧) > 0. First, note that
p
n{Ĥj(0,1, ⌧) Hj(0,1, ⌧)} =
n 1/2
Pn




I(⇧i = j)dNDi (u)
SC(u)
















































Also, note that gj(t) (0 < t  ⌧) can be written as sum of monotone cadlag
processes and is Donsker, thus
p
n{ ̂cj(t)  cj(t)} (0 < t  ⌧) converges weakly
to a tight and zero-mean Gaussian process, whose covariance function can be
consistently estimated by n 1
Pn











outcomes and Medical Costs
Data: Application to AIDS and
Cancer Studies
5.1 Analysis of Quality of life and Survival: CPCRA
ddI/ddC Trial
We illustrate the proposed methods by analyzing data from a clinical trial con-
ducted by Terry Beirn Community Programs for Clinical Research on AIDS,
a federally funded national network of community-based research groups. The
study compared didanosine (ddI) and zalcitabine (ddC) as treatments for HIV-
infected patients who were intolerant or had failed treatment with zidovudine.
The trial randomized 230 patients to receive ddI treatment and 237 to receive
ddC. The primary endpoint is time to disease progression or death. The sec-
ondary endpoints include changes in the Karnofsky performance score and op-
portunistic infections, where a reduction in the Karnofsky score and the occur-
rence of opportunistic disease indicate a deterioration in health. Both survival
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time and quality of life are regarded as important indexes for treatment suc-
cess. The analysis in Abrams et al. (1994) suggested that ddC treatment may
have provided a survival advantage over ddI treatment, with borderline signif-
icance based on a proportional hazards model. We investigated the treatment
e↵ects on the cumulative weighted marker process for a more comprehensive
assessment of the benefits and risks of the treatments. In our analysis, death
is the terminal event of interest, and Karnofsky score and incidence of oppor-
tunistic infections are used as measures for quality of life. The analysis with
Karnofsky score illustrates the proposed methodology in the case whre the lon-
gitudinal marker is intermitently observed, while the analysis with incidence of
opportunistic infections illustrates the situation where the longitudinal marker
is completely observed throughout the follow-up period.
In the first set of analysis, we divide the Karnofsky score by 100 and trans-
form it to a 0 to 1 scale and set w(·) = 1. The results are summarized in Table
5.2. The mean of the cumulative weighted marker process at 500th day (⇡ 1.37
year) is 0.876 for the ddI group and is 0.907 for the ddC group. The two-
sided p-value deriived from the proposed two-sample test is 0.38. Our analysis
suggests that ddC performs slightly better than ddI in terms of the proposed
summary measure, though the di↵erence is not statistically significant. Figure
5.1 displays the estimated cumulative mean function µ(t), survival function and
mean Karnofsky score of survivors in the ddI and ddC treatment groups. The
plots show that ddC performs better in terms of survival but worse in terms of
survivors’ physical quality of life, and the estimated summary measures for the
two treatments are very close.
In the second set of analysis, we consider benefit-risk assessment based on
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Figure 5.1: Estimated cumulative mean functions µ(t) using Karnofsky score
and time to death (left), survival functions (middle) and mean Karnofsky score
of survivors E{Y (t) | D   t} (right) for ddI (solid line) and ddC (dashed line)
treatment groups.
opportunistic infections and death. A total of 363 confirmed or probable op-
portunistic diseases indicating disease progression (Neaton et al., 1994) were
reported. The number of opportunistic infections per subject ranges from 0 to
5, with median 1 and mean 0.78. Denote by O(u) the total number opportunis-
tic infections occurred at or before time u, and set Y (·) = 0.8O(·). Then the
occurrence of opportunistic infection at time t discounts a patient’s score Y (t)
by 0.8. Then the estimated summary measure is 0.998 for the ddI group and
1.028 for the ddC group. The p-value derived from the proposed two-sample
test is 0.27. Our analysis again suggests that ddC outperforms ddI in terms of
the proposed summary measure on survival and opportunistic disease, although
the advantage is not statistically significant.
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Table 5.1: Analysis of ddI/ddC trial of CPCRA
ddI ddC
Marker Estimate 95% CI Estimate 95% CI p-Value
Karnofsky score 0.876 (0.828, 0.925) 0.907 (0.858, 0.955) 0.38
OI 0.998 (0.932, 1.063) 1.028 (0.959, 1.097) 0.27
Note: Estimate is the estimated µ(⌧) (⌧ ⇡ 1.37year) , 95% CI is the 95% confidence interval
based on standard error estimate. OI stands for opportunistic infection.
5.2 Analysis of Censored Medical Cost Data:
SEER-Medicare Linked Database
The proposed methods are applied to SEER–Medicare linked database; see
Warren et al. (2002) for an overview of the data. For illustration, we assess
the medical cost of breast cancer patients diagnosed at age 65+ in 1994 among
Medicare enrollees. We take the time of first diagnosis of breast cancer to be
the time origin, and D is the time from first diagnosis of breast cancer to death.
N(·) is the counting process that characterizes the number of inpatient or out-
patient cares, and upon the occurrence of inpatient or outpatient cares, Y (t) is
the cost charged for medical treatment. As a well known fact, cardiovascular
disease competes with breast cancer as the leading cause of death for older fe-
males diagnosed with breast cancer (Patnaik et al., 2011). In particular, we are
interested in three competing terminal events within ten years since diagnosis of
breast cancer: (i) breast cancer mortality (⇧ = 1), (ii) death from a cardiovas-
cular disease (⇧ = 2), (iii) mortality from other causes (⇧ = 3). The subjects
are divided into two groups by the historic stage determined at diagnosis: 6156
subjects with localized stage and 2540 subjects with regional stages. In the
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following analysis, the cost accumulation process from first diagnosis to ⌧ = 10
years is of interest, and people who survives more than 10 years are classified
to the fourth category (long-term survivors).
We begin with estimating the cumulative incidence in standard competing
risks model. For patients diagnosed with localized stage, the 10-year cumula-
tive incidence was 8.5% (SE : 0.5%) for breast cancer (BC) deaths, 12.4% (SE :
0.5%) for cardiovascular disease (CVD) death, and 25.7% (SE : 0.7%) for other
cause mortality. For patients diagnosed with regional stage, the 10-year cumula-
tive incidence was 30.8% (SE : 1.2%) for breast cancer deaths, 13.4% (SE : 0.9%)
for cardiovascular disease death, and 24.6% (SE : 1.1%) for other cause mor-
tality. Thus at the end of the tenth year, the regional stage group has larger
proportion of patients with breast cancer death than the localized stage group,
and the two groups has similar proportions of cardiovascular disease death and
death due to other causes.
We then analyze the medical cost up to a time horizon ⌧ = 10 years with
our proposed methods. The results are presented in Table 2. When we do not
distinguish the three types of death, the estimator in Section 3.1 is employed to
estimate the total medical cost. It can be seen that the regional stage group has
higher average ten-year medical cost than the localized stage group. We further
take into account the three competing risks, ⇧ = 1, 2, 3, and the estimates are
obtained by using the improved estimators in Chapter 4.4. For each of the lo-
calized and regional stage groups, the average cost of patients with CVD death
( c2(⌧)) di↵ers slightly from the average cost of patients with other mortality
( c3(⌧)), but is much higher than the average cost of patients with BC mortality
( c1(⌧)). In contrast, for the overall spending of medical cost,  j(⌧), patients
66
with other mortality spent the most when compared with BC and CVD mortal-
ity, which is largely explained by the large proportion of patients of with other
cause of death at the tenth year.
For a better plot presentation, we consider the average medical cost over time
from first diagnosis of breast cancer to the tenth year after diagnosis. The med-
ical costs over time of localized and regional stage group are presented in Figure
1, and regional stage group has consistently higher medical cost over time. The
estimated medical costs over time for competing risk types ⇧ = 1 and 2 are
shown in Figure 2. For the overall spending of medical cost ( j(t), j = 1, 2), it
can be seen that the expected cost attributed to BC mortality of regional stage
patients is much higher than that of localized stage patients, which is mainly
due to the higher 10-year cumulative incidence of BC mortality of regional stage
patients. The average costs of patients with each cause of death ( cj(t), j = 1, 2)
are similar between localized and regional group, though the cost over time for
CVD mortality patients is consistently higher than the cost for BC mortality
patients.
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Figure 5.2: Estimated total mean cost over time since first diagnosis of breast
cancer and point-wise 95% confidence intervals




























NOTE: Costs for patients with localized stage (estimate: solid line; CI: dotted
line) and regional stage(estimate: long-dash line; CI: dashed line).
Table 5.2: Analysis of SEER-Medicare Data
Localized Regional
Estimate SE Estimate SE
Total  (⌧) 86794.9 2173.1 91761.8 3504.0
BC mortality  1(⌧) 6958.5 603.33 22573.6 1502.6
 c1(⌧) 81580.1 5540.9 73279.5 3952.3
CVD mortality  2(⌧) 14661.5 1088.7 15296.6 1681.2
 c2(⌧) 117963.1 7082.9 114158.2 10012.0
Other mortality  3(⌧) 31374.9 1652.7 29170.1 2562.0
 c3(⌧) 122222.9 5452.9 118937.0 8907.5
Long-term survivors  4(⌧) 63330.0 2343.5 24682.7 2198.8
 c4(⌧) 45911.9 1364.7 79116.7 6342.7
NOTE: Estimate is the cost in US Dollar at ⌧ = 10 year, SE is the standard error estimate.
BC is for breast cancer and CVD is for cardiovascular disease.
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Figure 5.3: Cost analysis for breast cancer mortality and cardiovascular disease
mortality


















































































































NOTE: The left panels are estimated mean cost since first diagnosis of breast
cancer for BC mortality  1(t) (Upper) and CVD mortality  2(t) (Lower) with
point-wise 95% confidence intervals (CI). The right panels are estimated con-
ditional mean cost of BC mortality  c1(t) (Upper) and CVD mortality  
c
2(t)
(Lower). The solid lines are estimates for patients with localized stage (CI:
dotted line) and the dashed line are estimates for patients with regional stage
(CI: dashed line).
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Figure 5.4: Cost analysis for other causes mortality and long-term survivors




























































































































NOTE: The left panels are estimated mean cost since first diagnosis of breast
cancer for other-cause mortality  3(t) (Upper) and long-term survivors  4(t)
(Lower) with point-wise 95% confidence intervals (CI). The right panels are
estimated conditional mean cost of other-cause mortality  c3(t) (Upper) and
long-term survivors  c4(t) (Lower). The solid lines are estimates for patients
with localized stage (CI: dotted line) and the dashed line are estimates for




In this dissertation, we first consider benefit-risk assessment based on longitu-
dinal marker measurements and time to event data. The proposed method is
especially useful when conflict results about the treatment e↵ects are reported
for the two outcomes. Our estimation and testing procedures are more robust
than the existing methods, such as Hwang et al. (1996), in the sense that the sta-
tistical procedures can be derived from one single data set. Statistical inference
properties are established for point estimate and hypothesis testing, hence the
proposed methodology is expected to be attractive for practitioners to facilitate
accurate decision-making.
The proposed methodologies have a wide range of applicability in biomedical
and publich health research. Besides the examples discussed in Section 3.1, the
longitudinal measure Y (·) can also be the value of an surrogate biomarker for
the survival outcome of interest; for example, CD4 cell count has been used as
a surrogate for progression to AIDS or death in many AIDS studies. In the case
where the follow-up duration is not long enough to accumulate adequate num-
ber of events for meaningful analysis, the clinical study may have insu cient
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power to detect treatment e↵ects on the survival outcome. Compared with the
conventional survival analysis, the proposed methods utilize additional infor-
mation from the surrogate marker and possess the potential to increase power
in detecting real treatment e↵ects. Finally, instead of using a single marker
process, a benefit-risk summary measure integrating multiple marker processes
and time to event is under investigation.
In this work, we have focused on the one- and two- sample problems, and
the proposed summary measure is estimated using kernel smoothing techniques.
It would be interesting to consider extending the methodology to a regression
setting.
For example, we may consider the following frailty model. Let V represents
the covariates, then the summary measure adjusted for covariates can be defined
as µ(⌧ | V ) =
R ⌧
0 E{Y (u)I(D   u) | V }du. We can estimate µ(⌧ | V ) based
on a joint model of longitudinal and survival data. For example, we assume
E{Y (t) | V, Z} = g(t) + V   + Z and hazard function h(t | V, Z) = Zh0(t)eV  ,
where the frailty random variable Z is independent of V and has a gamma
distribution with unit mean and variance 1/↵. When ↵ ! 1, the correlation
of Y (·) and D goes to 0. It can be further shown that E{Y (t)I(D   t) | V } =
↵↵+1{↵+H0(t)eV  } ↵ 1 + ↵↵{↵+H0(t)eV  } ↵{V   + g(t)}. Suppose V is the
treatment indicator, coded 0 if control and coded 1 if treated, then µ(⌧ | V = 1)
and µ(⌧ | V = 0) are deterministic functions of ( ,  ). If   > 0 and   < 0, both
longitudinal and survival components for the treatment group would be better.
If   < 0 and   < 0, survival outcome for the treatment group is better but
longitudinal outcome is worse, then it would be di cult to make decision based
on the two separate components. Our proposed summary measure o↵ers a way
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to summarize joint modeling results for a conclusive benefit-risk assessment,
that is, we can compare µ(⌧ | V = 1) and µ(⌧ | V = 0) for decision-making.
The work can also be extend to the situation where the terminal event
time is subject to left truncation. One can modify the risk-set indicator to get
estimation under left truncation.
This dissertation also proposed nonparametric estimators of the mean recur-
rent marker process, with specific focus on competing risks model. In Section
4.2, we considered a nonparametric estimation approach which uses marker his-
tory information from both censored and uncensored subjects, but the estimator
cannot be generalized to handle problems involving competing risks because the
risk type information is unknown for those censored subjects. A consistent and
asymptotically normally distributed estimator of type-j mean function is then
constructed in Section 4.3 under competing risks model, where the proposed
estimator only uses risk type information from uncensored subjects. Further-
more, using auxiliary information from the estimate of the non-competing risks
mean function, an optimal estimator among a class of weighted estimators is
proposed in Section 4.4 to improve the estimation e ciency over the estimator
proposed in Section 4.3.
In this article, we mainly considered one-sample estimation, the authors
are considering to extend the non-parametric estimation to regression setting.
For example, we may consider the following marginal models. We assume the
survival time in the target population follows the Cox proportional hazards
model
h(t | V ) = h0(t) exp(↵V ),
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where  (t) is an unspecified baseline hazard function and ↵ is the coe cient.
For the marked recurrent event process, we define the conditional rate function
given D = t and V = v, that is, ⌘(u, t | v)du = E{Y (u)dN(u) | D = t, V = v}.
Then we consider the following proportional rate model
⌘(u, t | v) = ⌘0(u, t) exp( v), 0  u  t (6.0.1)
where h(u, t) is an unspecified baseline rate function at time u given D = t.
Note that h(u, t | v) is the rate of accumulation of cost or utility at u given
that survival time is t and covariate is v. In many studies, survival time is
typically the primary endpoint whereas lifetime medical cost is a secondary
outcome, thus it is meaningful to compare the cost/utility accumulation process
among subjects with the same survival time. Moreover, medical costs usually
increase during the time period prior to death because of the intensive care
for dying patients, and the patterns of medical costs is often closely linked
to the death time (Liu et al., 2007). Therefore, it is natural to model cost
trajectory conditional on terminal event time. Define H(t | v) =
R t
0 ⌘(u, t |
v)du = E{
R D
0 Y (u)dN(u) | D = t, V = v}, which is the expected lifetime cost
or utility given survival time t and covariate v. Note that (6.0.1) implies
H(t | v) = H0(t) exp( v), (6.0.2)
where H0(t) =
R t
0 ⌘0(u, t)du is the baseline lifetime cost/utility given survival
time is t. Compared to equation (6.0.1), equation (6.0.2) makes stronger as-
sumption of the stochastic process Y (·)dN(·) before the terminal event. Esti-
mating equations can be constructed using similar methods in Chan (2009).
In conclusion, the nonparametric methods proposed in this dissertation for
marker processes with a terminal event may initiate a variety of future works
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on both statistical methods and applications, which could facilitate a compre-
hensive understanding of the marker process and survival time.
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